Introduction/Background Ovarian cancer is the eighth most common type of cancer in women around the world and a major cause of cancer-related deaths in women. This disease affects about 10% of females worldwide. Because there isn’t a clear sign for ovarian cancer, detection has been delayed, and mortality rates have been less than ideal. Researchers have already written about how the serum HE-4 protein and the ROMA algorithm can be used as biomarkers to help diagnose and predict cancer. However, there aren’t many studies that have been done on the Indian community.

Methodology A cross-sectional observational analytical study was conducted with 71 study participants. From fasting pre-operative blood samples, HE-4 and serum CA-125 were both analyzed by ELISA and CLIA, respectively. ROMA algorithm was calculated form Serum CA-125 and serum HE-4. Ultrasonography was done using iU22 ultrasound system (2–5 MHz probe).

Results Serum HE-4 shows high diagnostic accuracy (84.5%) in the prediction of malignancy with 100% sensitivity and 81.4% specificity, whereas the ROMA score had a lower specificity of 79.7%. Serum HE-4 also showed a significant association with malignant features of ovarian tumors on trans-abdominal ultrasonography (p<0.05) and histological subtypes of benign and malignant tumors (χ2 = 23.122, p = 0.001).

Conclusion The use of serum HE-4 as a biomarker for the diagnosis of malignancy in ovarian tumors has been observed to exhibit a high degree of sensitivity and specificity. There is evidence that serum CA-125 can lower the specificity of analysis when it comes to the Risk of Ovarian Malignancy Algorithm (ROMA) score.

Disclosures None